Guía Europea de Prevención Cardiovascular en la Práctica Clínica

Backer, Guy De; Амбросиони, Е.; Borch‐Johnsen, Knut; Brotons, Carlos; Cífková, Renata; Dallongeville, Jean; Ebrahim, S.; Faergeman, O.; Graham, Ian; Mancia, Giuseppe; Manger-Cats, V.; Orth-Gomér, K.; Perk, Joep; Pyörälä, K; Rodicio, José L.; Sans, S.; Sansoy, Vedat; Sechtem, Udo; Silber, Siegfried; Thomsen, Troels; Wood, D.

doi:10.1016/s0214-9168(05)73309-x

Cited by 28 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several lipid-lowering drugs are now available (2)(3)(4). Most, such as the hydroxymethyl glutaryl CoA (HMG CoA) reductase inhibitors (statins), or bileacid-binding agents, reduce cholesterol levels within liver.…”

Section: Thyroid Hormones [Predominantly 353-triiodo-l-thyronine (T3)]mentioning

confidence: 99%

Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice

Johansson

Rudling

Scanlan

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

174

142

View full text Add to dashboard Cite

Thyroid hormones [predominantly 3,5,3-triiodo-L-thyronine (T3)] regulate cholesterol and lipoprotein metabolism, but cardiac effects restrict their use as hypolipidemic drugs. T 3 binds to thyroid hormone receptors (TRs) ␣ and ␤. TR␤ is the predominant isoform in liver, whereas T 3 effects on heart rate are mediated mostly by TR␣. Drugs that target TR␤ or exhibit tissue-selective uptake may improve plasma lipid levels while sparing the heart. Here, we asked how the TR␤-and liver uptake-selective agonist GC-1 influences cholesterol and triglyceride metabolism in euthyroid mice. GC-1 treatment reduced serum cholesterol levels by 25% and serum triglycerides by 75% in chow-fed mice and also attenuated dietinduced hypercholesterolemia. GC-1 reduced plasma high-density lipoprotein cholesterol levels; increased expression of the hepatic high-density lipoprotein receptor, SR-BI; stimulated activity of cholesterol 7␣-hydroxylase; and increased fecal excretion of bile acids. Collectively, these results suggest that GC-1 stimulates important steps in reverse cholesterol transport. Use of TR␤ and uptake selective agonists such as GC-1 should be further explored as a strategy to improve lipid metabolism in dyslipoproteinemia.bile acid ͉ lipoprotein ͉ triglycerides ͉ thyroid hormone ͉ selective modulation

show abstract

Section: Thyroid Hormones [Predominantly 353-triiodo-l-thyronine (T3)]mentioning

confidence: 99%

Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice

Johansson

Rudling

Scanlan

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

174

142

View full text Add to dashboard Cite

show abstract

“…Although these prediction models stratify patients according to different hard clinical end-points (events in the CUORE model and mortality in the SCORE model), they are assumed to be largely concordant and are both currently recommended for CV risk stratification by national [24] and [25] and European [13] guidelines. Therefore, given persistent uncertainties on reliability of risk classification based on conventional risk factors alone [2] and [3], routine ABI measurement appears to be an easy and reliable tool for identification of high risk subjects irrespective of conventional risk models.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, evaluation of subclinical atherosclerosis through ABI determination should have its place in the context of risk classification among asymptomatic subjects. Currently, most international guidelines recommend to consider PAD (diagnosed on the basis of low ABI) as a CHD risk equivalent, for which aggressive medical therapies are strongly recommended [10], [13], [14] and [27]. Despite this bulk of evidence, there remains a lack of awareness of this item among healthcare professionals, and ABI determination is largely underused for CV risk stratification [16] and [17].…”

Section: Discussionmentioning

confidence: 99%

“…According to the score obtained, patients were defined at 10-year CV low risk (≤ 10%), moderate risk (11-19%) and high risk (≥ 20%). The 10-year risk of fatal events was also evaluated according to the SCORE model for low-risk southern Europe countries [13]. According to the score obtained patients were defined at 10-year CV low risk (≤ 1%), moderate risk (2-4%) and high risk (≥ 5%).…”

Section: Assessment Of Cardiovascular Riskmentioning

confidence: 99%

“…Moreover, a 50% 10-year mortality risk in these patients, mainly for CV fatal events, has been reported in several studies [11] and [12]. Therefore, recent CV prevention guidelines have included PAD as a CHD risk equivalent and suggest measurement of ABI as a simple way to identify high-risk subjects, irrespective of conventional risk prediction models, for whom aggressive medical treatment is strongly recommended [13], [14] and [15]. However, ABI measurement is not routinely performed in most primary prevention setting, and there remains a widespread lack of awareness of these recommendations among healthcare professionals [16] and [17], even in selected primary prevention settings caring for moderate to high risk patients (such as Lipid, Hypertension or Diabetes Clinics) wherein ABI determination, accordingly with some clinical recommendations [18], is mostly performed as a second-line test in patients at intermediate risk.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Implications of routinely measuring Ankle-Brachial Index (ABI) among patients attending at a Lipid Clinic

Sona

Comba

Brescianini

et al. 2009

European Journal of Internal Medicine

View full text Add to dashboard Cite

The definitive versionisavailableat:La versione definitiva è disponibile alla URL: [http://www.sciencedirect.com/science/article/pii/S0953620508002677?via=ihub] Implications of routinely measuring Ankle-Brachial Index (ABI) among patients attending at a Lipid Clinic Alessandro Sona, Monica Comba, Alessia Brescianini, Laura Corsinovi, Mauro Zanocchi, Gianfranco Fonte, Mario BoCorresponding author contact information, E-mail the corresponding author Abstract BackgroundLow (≤ 0.90) Ankle Brachial Index (ABI) values identify patients at high risk for cardiovascular (CV) disease and mortality. Implications for CV risk classification from routinely measuring ABI in the context of a Lipid Clinic have not been fully investigated. We aimed to evaluate whether and to what extent routine ABI determination on top of conventional risk prediction models may modify CV risk classification. MethodsConsecutive asymptomatic non-diabetic individuals free from previous CV events attending for a first visit at a Lipid Clinic underwent routine ABI determination and conventional CV risk classification according either to national CUORE model (including age, gender, smoking, total and high density lipoprotein cholesterol, systolic blood pressure and current use of blood pressure lowering drugs) and SCORE model for low risk countries. ResultsIn the overall sample (320 subjects, mean age 64.8 years) 77 subjects (24.1%) were found to have low ABI value. Forty-two of 250 subjects (16.8%) and 47 of 215 individuals (21.3%) at low or moderate risk according to the CUORE and SCORE models, respectively, were found to have low ABI values, and should be reclassified at high risk. ConclusionIn a series of consecutive asymptomatic individuals in a Lipid Clinic, we observed a high prevalence of low ABI values among subjects deemed at low or moderate risk on conventional prediction models, leading to CV high-risk reclassification of roughly one fifth of patients. These findings reinforce recommendations for routine determination of ABI at least within referral primary prevention settings.

show abstract

Impaired Antiatherogenic Function of High-Density Lipoproteins in the Presence of Various Risk Factors for Coronary Heart Disease

et al. 2005

View full text Add to dashboard Cite

We studied acception of cholesterol from Fu5AH hepatoma cells by blood serum from subjects with normal level of high-density lipoprotein cholesterol and hyperlipidemia (alone or in combination with other risk factors for coronary heart disease). Cholesterol-binding activity of high-density lipoproteins decreased in subjects with hyperlipidemia alone or in combination with excess body weight and/or arterial hypertension. Impairment of high-density lipoprotein activity was associated with changes in their phospholipid composition.

show abstract

Guía Europea de Prevención Cardiovascular en la Práctica Clínica

Cited by 28 publications

References 0 publications

Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice

Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice

Implications of routinely measuring Ankle-Brachial Index (ABI) among patients attending at a Lipid Clinic

Impaired Antiatherogenic Function of High-Density Lipoproteins in the Presence of Various Risk Factors for Coronary Heart Disease

Contact Info

Product

Resources

About